NXP800 yields neither severe thrombocytopenia, nor any responses.
ApexOnco Front Page
Recent articles
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
The company defends its cancer strategy, and says it's not a me-too developer.
As BAY2927088 enters phase 3 its lung cancer use will no longer be limited to exon 20.
Luminice-203 yields its first topline data, but where are all the patients?
Pfizer moves to take PF-07934040 into its first clinical trial.
Breyanzi and Imdelltra head up May’s approvals, while camrelizumab’s CRL is a lowlight.
The company’s vuso-vec looks similar to Amtagvi, and could have safety and convenience advantages.
